Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synta Pharmaceuticals has initiated a second Phase I clinical study of its novel heat shock protein 90 inhibitor, STA-9090, with a once-a-week dosing schedule.
Subscribe to our email newsletter
The open-label Phase I study in patients with solid tumors is designed to identify the maximum tolerated dose of STA-9090 based on a once-a-week, one-hour intravenous dosing schedule. In addition to an evaluation of safety and tolerability, patients will be assessed for tumor response based on the RECIST criteria. STA-9090 is a synthetic, small molecule Hsp90 inhibitor with a novel chemical structure that is unrelated to the Hsp90 inhibitor geldanamycin or its family of related compounds, such as 17-AAG.
Eric Jacobson, senior vice president and chief medical officer of Synta, said: “Initiating this second Phase I trial for STA-9090 will allow us to explore different dosing regimens for this compound.”